Key Highlights

  • Vectus Biosystems (ASX:VBS) shares were down 14.29% at $0.09 during the Trading session on 22 October 2026.
  • In an announcement dated 30 September 2026, the company said the FDA granted its pre-IND Type B meeting request for VB0004 in idiopathic pulmonary fibrosis.
  • The FDA's written responses are expected by mid-November 2026, after the company finalises and submits its meeting package.

Vectus Biosystems Limited (ASX:VBS) shares were down 14.29% at $0.09 during the trading session on 22 October 2026, at the time of the data. By comparison, the The S&P/ASX 200 stood at 8,792.20, down 0.44%, and the All Ordinaries stood at 8,916.20, down 0.45%. Vectus Biosystems is an Australian clinical-stage biotechnology company developing therapies for fibrotic diseases. In an announcement dated 30 September 2026, the company said the US Food and Drug Administration had granted its request for a pre-Investigational New Drug Type B meeting for its lead compound, VB0004, in idiopathic pulmonary fibrosis.

About the Company

Vectus Biosystems Limited is an Australian clinical-stage biotechnology company listed on the ASX under the code VBS. Its address is Unit 5, Ground Floor, 26-34 Dunning Avenue, Rosebery, New South Wales. Dr Ronald Shnier is Chairman, and Dr Tara Speranza serves as Chief Executive Officer and Chief Technology Officer.

The company states that it is developing novel therapies for fibrotic diseases, with an initial focus on advancing VB0004 for idiopathic pulmonary fibrosis, or IPF, which it describes as a progressive and often fatal lung disease with significant unmet medical need.

Business Overview

VB0004 is described as a first-in-class oral vasoactive intestinal peptide (VIP)-mimetic and natriuretic peptide receptor C (NPR-C) agonist. The company reports that it has demonstrated the ability to reverse established fibrosis in pre-clinical models and has completed a Phase Ia clinical study in healthy volunteers that established a favourable safety and pharmacokinetic profile.

Beyond IPF, Vectus is advancing a broader pipeline of antifibrotic Assets targeting cardiovascular, renal and liver fibrosis using a platform approach. It has also entered a licensing agreement with an international biotechnology company for one of its renal fibrosis assets, which the company says shows a pathway for potential future milestone and Royalty revenues.

FDA Pre-IND Meeting Granted

In its announcement dated 30 September 2026, Vectus said the FDA had granted the company's request for a pre-IND Type B meeting. In this meeting, written responses regarding the proposed development program for VB0004 in IPF will be tabled.

The company said the FDA's detailed responses are expected by mid-November 2026. Together with its US Regulatory Agent, Cardinal Health Regulatory Services, Vectus will now finalise and submit its meeting package to the agency.

Management Comments and US Pathway

Dr Speranza said in the 30 September 2026 announcement that the FDA's decision represented an important step in progressing the US regulatory pathway for VB0004 and gave the company a chance to obtain formal guidance on the proposed development program in IPF. She said the company is now focused on finalising its meeting package and that the feedback will help inform the next stages of the compound's clinical and regulatory development.

The company added that US regulatory activities are now underway to establish the foundation for future clinical development in the United States. The announcement did not provide details of a planned clinical trial design, timetable or funding for later stages of development, and it said the feedback will help inform the next stages.

Related Sector Context

Vectus operates in clinical-stage biotechnology, where companies typically carry no product Revenue while they progress candidates through regulatory interactions and clinical studies. Pre-IND meetings are an early step in dialogue with the FDA before a company lodges an application to begin human trials in the United States.

During the 22 October 2026 session, the S&P/ASX 200 was down 0.44% and the All Ordinaries down 0.45%. Vectus's decline of 14.29% was considerably larger than the benchmark moves, and at a share price of $0.09 a change of a single cent represents a large percentage movement.

Risks to Weigh In

The company is at a development stage in which outcomes are uncertain. VB0004 has completed Phase Ia testing in healthy volunteers, and its effect in patients with IPF has not been established in clinical studies. The FDA's written responses may include requirements or recommendations that change the proposed development program.

The announcement does not describe funding arrangements for later clinical stages. The timing of the FDA's responses, the company's submission of its meeting package and subsequent regulatory steps all remain subject to processes outside the company's direct control.

Catalysts on Watch

The next stated milestone is the receipt of the FDA's detailed written responses, expected by mid-November 2026. Before that, Vectus and Cardinal Health Regulatory Services will finalise and submit the meeting package. Following the feedback, the company expects to determine the next stages of VB0004's clinical and regulatory development, and any further announcements would be issued to the market.

Putting It Together

Vectus Biosystems shares fell 14.29% to $0.09 during the 22 October 2026 session, against benchmark declines of less than half a percent. The company's announcement of 30 September 2026 covered the FDA's grant of a pre-IND meeting for VB0004, with written responses due by mid-November 2026.